ChromoGenics AB (publ) Rights Issue January - February 2019

ChromoGenics offers dynamic, built-in solar control for windows and facade glass. ConverLight adapts the light transmittance for maximum comfort and energy efficiency. I-Window is a world class static solar protection glass at a competitive price.

• Indoor comfort: Block out unwanted sunlight and heat while keeping the view.
• Design: Full architectural freedom for facades without awnings and blinds.
• Energy efficiency: Significantly less need for air conditioning – which according to the Economist is one of the major environmental culprits of our time.
• Price: Glasses with integrated solar control are more cost effective than the other alternatives over time.

• Download the information brochure here
• Download the Prospectus here
• Download the additional Prospectus here
• Download the application form here
• Download the press release about Prospectus regarding Rights Issue here
• Download the Communiqué from the extra general meeting here
• Download the auditors statement on the Board’s report on significant events in accordance with ch. Section 6 of the Swedish Companies Act (2005 551) here
• Download the press release The Board’s decision about the Rights Issue here

Issue amount at full subscription
77,7 MSEK

Subscriptions and warranty commitments
Subscription commitments of approximately 1,7 MSEK and warranty commitments of approximately 58,9 MSEK have been entered into, which corresponds to approximately 78% of 77,7 MSEK. However, the company has neither requested nor received bank collateral for these commitments.

Preference rights and unit rights
Anyone who was registered as a shareholder at the record date January 24th of 2019 has preference rights to subscribe for shares in the Rights Issue and will receive three (3) subscription rights for each share held. One (1) subscription right entitles to subscription of one (1) share. In addition, shareholders and other investors are being offered without preferential right to register an interest in subscribing for new shares.

Subscription without precedence
Subscription without precedence takes place by a special application form or electronically via www.aktieinvest.se/chromogenics2019. If you want to invoke priority and your shareholding is nominee-registered, subscription must take place in accordance with your nominee’s routines.

Subscription course
0,60 SEK per share

Subscription time
28th – 15th of February 2019

Trade with subscription rights
28th – 13th of February 2019

Trade with BTA
January 28, 2019 until later dates announced in connection with the registration of the issue.

ISIN-codes at Nasdaq First North
Share – CHRO SE0009496268
Subscription right – CHRO TR SE0012194454
Paid subscription share – CHRO BTA SE0012194462

The Company’s interim report for January – September 2018, including the audit reports for the Company’s year-end reports for the financial years of 2016 and 2017, forms a part of the Prospectus and should be read as part of this. Download these documents here

The following documents are available for inspection at the Company’s office (Ullforsgatan 15, 752 28 Uppsala) as well as in electronic form at the Company’s website (www.chromogenics.com). Copies can be obtained from or reviewed at the office during regular office hours on weekdays throughout the Prospectus’ validity period:

• Registration certificate
• Memorandum of association
• Articles of Association for ChromoGenics AB (publ)
• ChromoGenics AB (publ) audited accounts for the financial year of 2017, including the auditor’s report
• ChromoGenics AB (publ) audited accounts for the financial year of 2016, including the auditor’s report